Arvinas Q3 net loss widens to $66.2M; cash at $1.28B; on track for Phase 3 starts

ARVINAS, INC.

2022-Q3 EPS reported -$3.76 revenue$85,800,000

Net loss of $66.2M for Q3 2022 vs $46.8M in Q3 2021, driven by higher R&D and G&A costs.
Cash, cash equivalents and marketable securities were $1,276.2M as of Sept 30, 2022, sufficient beyond 2024.
R&D expenses nearly doubled to $77.5M, reflecting investment in platform and ER/AR programs.
On track to initiate two Phase 3 trials for ARV-471 in metastatic breast cancer by end of 2022.
Revenue from Pfizer collaboration drove revenues to $30.3M from $9.3M year-over-year.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

ARVINAS, INC. reported financial results for quarter ended September 30, 2022.

Period: quarter ended September 30, 2022
Result: reported results

Exact text from the filing

On November 8, 2022 , Arvinas, Inc. announced its financial results for the quarter ended September 30, 2022.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

ARVINAS, INC. filing history →

Source: SEC EDGAR

accession 0001655759-22-000053

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.